NCT02618811

Brief Summary

So far, the impact of sarcopenia has been analysed only in patients undergoing traditional surgical procedures (laparotomy) or those with metastatic spread. As the ERAS protocol combined with minimally invasive access decreases postoperative metabolic disorders, it seems possible that it can limit the deleterious impact of sarcopenia as well. The aim of this study was to investigate whether the use of ERAS protocol in colorectal cancer patients influences the postoperative risk due to sarcopenia.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
171

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2014

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2015

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

November 22, 2015

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 1, 2015

Completed
Last Updated

December 1, 2015

Status Verified

November 1, 2015

Enrollment Period

1.7 years

First QC Date

November 22, 2015

Last Update Submit

November 28, 2015

Conditions

Keywords

sarcopeniamyosteatosisenhanced recovery after surgerycolorectal cancerminimally invasive surgerycomplications

Outcome Measures

Primary Outcomes (1)

  • Complications

    up to 30 days post surgery

Secondary Outcomes (7)

  • Hospital length of stay (days)

    up to discharge from hospital, an average 6 days

  • Compliance with ERAS protocol (%)

    up to discharge from hospital, an average 6 days

  • Tolerance of oral diet on the 1st postoperative day

    up to discharge from hospital, an average 6 days

  • Time to first flatus

    up to discharge from hospital, an average 6 days

  • Readmission rate

    up to 30 days post surgery

  • +2 more secondary outcomes

Study Arms (4)

Group 1

not sarcopenic

Group 2

sarcopenic

Group 3

not myosteatotic

Group 4

myosteatotic

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

The analysis included prospectively collected data from consecutive patients electively operated for colorectal cancer in the years 2014-2015. All patients were operated using laparoscopic surgery, and the perioperative care was based on pre-established ERAS protocol consisting of 13 items

You may qualify if:

  • confirmed adenocarcinoma of colon or rectum
  • complete preoperative radiology assessment with abdominal CT scan
  • laparoscopic resection
  • perioperative care according to ERAS principles

You may not qualify if:

  • unavailability of a preoperative abdominal CT scan (within 30 days prior surgery)
  • emergency or initially open surgery
  • patients treated with endoscopic techniques: transanal endoscopic microsurgery (TEM), transanal total mesorectal excision (TaTME)
  • concomitant inflammatory bowel diseases.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

2nd Department of General Surgery, Jagiellonian University

Krakow, 31-501, Poland

Location

Related Publications (7)

  • Greco M, Capretti G, Beretta L, Gemma M, Pecorelli N, Braga M. Enhanced recovery program in colorectal surgery: a meta-analysis of randomized controlled trials. World J Surg. 2014 Jun;38(6):1531-41. doi: 10.1007/s00268-013-2416-8.

    PMID: 24368573BACKGROUND
  • Vlug MS, Wind J, Hollmann MW, Ubbink DT, Cense HA, Engel AF, Gerhards MF, van Wagensveld BA, van der Zaag ES, van Geloven AA, Sprangers MA, Cuesta MA, Bemelman WA; LAFA study group. Laparoscopy in combination with fast track multimodal management is the best perioperative strategy in patients undergoing colonic surgery: a randomized clinical trial (LAFA-study). Ann Surg. 2011 Dec;254(6):868-75. doi: 10.1097/SLA.0b013e31821fd1ce.

    PMID: 21597360BACKGROUND
  • Huang DD, Wang SL, Zhuang CL, Zheng BS, Lu JX, Chen FF, Zhou CJ, Shen X, Yu Z. Sarcopenia, as defined by low muscle mass, strength and physical performance, predicts complications after surgery for colorectal cancer. Colorectal Dis. 2015 Nov;17(11):O256-64. doi: 10.1111/codi.13067.

    PMID: 26194849BACKGROUND
  • Jones KI, Doleman B, Scott S, Lund JN, Williams JP. Simple psoas cross-sectional area measurement is a quick and easy method to assess sarcopenia and predicts major surgical complications. Colorectal Dis. 2015 Jan;17(1):O20-6. doi: 10.1111/codi.12805.

    PMID: 25328119BACKGROUND
  • Thoresen L, Frykholm G, Lydersen S, Ulveland H, Baracos V, Prado CM, Birdsell L, Falkmer U. Nutritional status, cachexia and survival in patients with advanced colorectal carcinoma. Different assessment criteria for nutritional status provide unequal results. Clin Nutr. 2013 Feb;32(1):65-72. doi: 10.1016/j.clnu.2012.05.009. Epub 2012 Jun 12.

    PMID: 22695408BACKGROUND
  • Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, Murphy R, Ghosh S, Sawyer MB, Baracos VE. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013 Apr 20;31(12):1539-47. doi: 10.1200/JCO.2012.45.2722. Epub 2013 Mar 25.

    PMID: 23530101BACKGROUND
  • Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol. 2015 Feb;41(2):186-96. doi: 10.1016/j.ejso.2014.10.056. Epub 2014 Nov 3.

    PMID: 25468746BACKGROUND

MeSH Terms

Conditions

SarcopeniaColonic NeoplasmsColorectal Neoplasms

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and SymptomsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Study Officials

  • Michał Pędziwiatr, MD, PhD

    2nd Department of Surgery, Jagiellonian University, Krakow, Poland

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD PhD

Study Record Dates

First Submitted

November 22, 2015

First Posted

December 1, 2015

Study Start

January 1, 2014

Primary Completion

October 1, 2015

Study Completion

November 1, 2015

Last Updated

December 1, 2015

Record last verified: 2015-11

Locations